Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft.
Mohiuddin MM, Singh AK, Corcoran PC, Thomas Iii ML, Clark T, Lewis BG, Hoyt RF, Eckhaus M, Pierson Iii RN, Belli AJ, Wolf E, Klymiuk N, Phelps C, Reimann KA, Ayares D, Horvath KA. · 2016
Read Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. by Mohiuddin MM, Singh AK, Corcoran PC, Thomas Iii ML, Clark T, Lewis BG, Hoyt RF, Eckhaus M, Pierson Iii RN, Belli AJ, Wolf E, Klymiuk N, Phelps C, Reimann KA, Ayares D, Horvath KA. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4822024.txt.
Introduction
Muhammad M. Mohiuddin leads a broad author team in Nature Communications in 2016 reporting long survival of pig hearts in baboons. Pig organs could ease the transplant shortage, but the primate immune system destroys them. The team used hearts from pigs edited three ways: a sugar that triggers attack removed, and two human guard proteins added to calm complement and clotting.
Five baboons received the hearts under a drug plan centered on an antibody that blocks the CD40 immune signal. Median graft survival reached about three hundred days, and the longest about nine hundred forty-five, far past the group's earlier marks. Cutting the antibody dose, even after a year, let anti-pig antibodies return and killed grafts. Dose discipline, the authors conclude, is as vital as the gene edits.
Catalog record
| CREATOR | Mohiuddin MM, Singh AK, Corcoran PC, Thomas Iii ML, Clark T, Lewis BG, Hoyt RF, Eckhaus M, Pierson Iii RN, Belli AJ, Wolf E, Klymiuk N, Phelps C, Reimann KA, Ayares D, Horvath KA. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft By Muhammad M. Mohiuddin, Avneesh K. Singh, Philip C. Corcoran, Marvin L. Thomas III, Tannia Clark, Billeta G. Lewis, Robert F. Hoyt, Michael Eckhaus, Richard N. Pierson III, Aaron J. Belli, Eckhard Wolf, Nikolai Klymiuk Published in: Nature Communications DOI: 10.1038/ncomms11138 ABSTRACT Preventing xenograft rejection is one of the greatest challenges of transplantation medicine. Here, we describe a reproducible, long-term survival of cardiac xenografts from alpha 1-3 galactosyltransferase gene knockout pigs, which express human complement regulatory protein CD46 and human thrombomodulin (GTKO.hCD46.hTBM), that were transplanted into baboons. Our immunomodulatory drug regimen includes induction with anti-thymocyte globulin and αCD20 antibody, followed by maintenance with mycophenolate mofetil and an intensively dosed αCD40 (2C10R4) antibody. Median (298 days) and longest (945 days) graft survival in five consecutive recipients using this regimen is significantly prolonged over our recently established survival benchmarks (180 and 500 days, respectively). Remarkably, the reduction of αCD40 antibody dose on day 100 or after 1 year resulted in recrudescence of anti-pig antibody and graft failure. In conclusion, genetic modifications (GTKO.hCD46.hTBM) combined with the treatment regimen tested here consistently prevent humoral rejection and systemic coagulation pathway dysregulation, sustaining long-term cardiac xenograft survival beyond 900 days. Previous pig-to-primate xenotransplantation studies have been beset with treatment-related complications and delayed xenograft rejection characterized by thrombotic microangiopathy (TM) and consumptive coagulopathy (CC)123. Previously, the longest survival for heterotopic cardiac xenografts using alpha 1-3 galactosyltransferase gene knockout (GTKO) or GTKO.hCD46 Tg pigs and immunosuppression (IS) that included αCD154 antibody was 179–236 days, however, the xenografts ultimately succumbed to the characteristic properties of delayed rejection45. We have recently reported survival beyond 1 year of GTKO.hCD46.hTBM pig heart xenografts that were heterotopically transplanted into a baboon. The immunomodulatory protocol utilized αCD40 antibody, documenting an attenuated anti-pig antibody elaboration, absence of TM in the graft and reduced incidence of systemic CC6. Longer-term and reliable prevention of xenograft rejection in this preclinical model has not previously been described. In the present study, using baboon recipients of GTKO.hCD46.hTBM porcine hearts, we evaluated an iterative modification of our previous immunomodulation strategy, one that primarily targets the anti-CD154-CD40 co-stimulation pathway. We report consistent prevention of xenograft rejection in association with ongoing αCD40 (2C10R4) antibody treatment resulting in graft survival beyond 2 years. RESULTS Anti-CD40 significantly prolongs graft survival The rationale for using GTKO) pigs to avoid anti-Gal antibody-mediated rejection, with additional human complement regulatory protein (hCD46) expression to suppress complement activation, has been previously reported5. Similarly, the benefits of anti-CD154/CD40, αCD20 and mycophenolate mofetil (MMF) immunosuppressive treatment on xenograft survival prolongation in baboons have been described45678. We used our established heterotopic cardiac xenotransplantation model using GTKO.hCD46 porcine donors910, engineered to additionally express the human thromboregulatory protein, human thrombomodulin (hTBM)1112. This genetic modification is intended to reduce thrombo-dysregulation often associated with xenografts. Specific pathogen-free baboons received a co-stimulation pathway-blocking drug regimen described in Table 1, including a non-depleting primatized αCD40 monoclonal antibody (2C10R4) (ref. 13). Postoperatively, a telemetry implant was used to continuously monitor graft contractility, electrocardiogram (EKG) and body temperature14. Telemetric surveillance was supplemented with constant video monitoring of the recipient baboon. Hearts from GTKO.hCD46 pigs engineered using one of two hTBM gene constructs with different promoters (ICAM in baboons #110, #210 and #910 and TBM in baboons #15009 and #510) were used (Fig. 1a; cloned from founder lines selected for high endothelial expression of hTBM). This was the first time this hTBM transgene was used and the efficacy of the two available promoters was not known. The ICAM-2 promoter was clearly superior in expression/functionality of TBM in endothelial cells, both by flow cytometry and generation of antigen presenting cell (APC), when compared with endothelial cells from the pTBM-TBM pigs. However, immunochemistry of heart tissue (n=1 for each promoter type) indicated more robust expression of hTBM generated by the porcine endogenous TBM promoter. Both promoters provided significant expression of TBM on the cardiac vascular endothelium. Overall, the transplanted TBM+ hearts with the TBM promoter perform as well or better than the ones bearing the ICAM-2 promoter. Histologic depiction of the representative expression of hTBM on porcine aortic endothelial cells (PAECs; Fig. 1b) and on the endothelial cells of donor pig littermates (Fig. 1c(i,ii)) is illustrated relative to human vascular endothelial cells (Fig. 1c(iii)). As expected, hTBM expression is not detected in the wild-type pig (Fig. 1c(iv)). As demonstrated in Fig. 2a, all five GTKO.hCD46.hTBM hearts had significantly prolonged xenograft survival (mean 433 days, median 298 days and range 159–945 days) compared to previously reported GTKO.hCD46 pig heart survival using αCD40 antibody at a lower dose (longest survival 146 days)7 and the same group of animals, described in this study, at an earlier stage of survival (longest survival >500 days)6. One animal that succumbed to an antibiotic-resistant infection with a contracting graft at 146 days was censored from the survival analysis; a source of infection was not established on necropsy. When αCD40 antibody was administered at a lower dose (25 mg kg−1) and tapered off over the course of 2 months, none of the GTKO.hCD46.hTBM grafts survived long term7. In contrast, significant survival was achieved when a higher dose of antibody (50 mg kg−1) was used6. We then elected to decrease the weekly dose of weekly αCD40 antibody in two animals to 25 mg kg−1 after 100 days. Both grafts slowly failed in association with recrudescence of anti-donor antibody. In contrast, the two recipients receiving a high dose of antibody maintained cardiac function despite gradual reduction in the antibody dose after 1 year, as illustrated in Fig. 2. The αCD40 antibody was finally discontinued in baboon #910 on day 560 and in baboon #510 on day 861. Both grafts rejected after 8–10 weeks of antibody termination on days 616 and 945, respectively. Progressive graft dysfunction occurred concomitant with the washout of αCD40 antibody (Fig. 2b) and subsequent return of anti-pig antibody (Fig. 2c). Laboratory and mechanistic correlates Histology of the grafts in baboons that rejected after αCD40 dose reduction on day 100 demonstrated features typical of xenograft rejection, including myocyte death, haemorrhage, fibrosis, with sparse cellular infiltration by macrophages, neutrophils and occasional lymphocytes (Fig. 3a(ii,iv)). The histology of the graft from baboon #15009 that succumbed to infection with a contracting graft on continued αCD40 antibody treatment demonstrated focal myocarditis (Fig. 3a(iii)). There was no evidence of TM in the graft or CC in any baboon during ‘full-dose' antibody treatment (Fig. 3a(i)). After terminating the αCD40 antibody treatment, long-term surviving hearts demonstrated a typical xenograft rejection pattern, including characteristic features of TM, vasculitis, intravascular thrombus, myocardial necrosis and epicardial haemorrhage. There was little or no interstitial lymphocytic infiltration identified in these grafts (Fig. 3b,c). The biopsies from both long-term animals demonstrated sustained levels of hTBM expression (Fig. 3d) similar to untransplanted hearts from littermates (Fig. 1c(i,ii)). As shown in Fig. 4a(i), the haematocrit (HCT) data for all five baboons indicate that a normal complete blood count profile was maintained during treatment. Distinct from our work using GTKO.hCD46 hearts and CD154-based IS5, platelet numbers were maintained within the normal range (Fig. 4a(ii)), and no spontaneous bleeding episodes were observed despite continuous heparin administration (activated clotting time (ACT) goal=2 × baseline level;